Home Cart Sign in  
Chemical Structure| 1234015-52-1 Chemical Structure| 1234015-52-1

Structure of Prexasertib
CAS No.: 1234015-52-1

Chemical Structure| 1234015-52-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY2606368 is a potent and selective ATP competitive inhibitor (IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.

Synonyms: Ly2606368; ACR 368

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Prexasertib

CAS No. :1234015-52-1
Formula : C18H19N7O2
M.W : 365.39
SMILES Code : N#CC1=NC=C(NC2=NNC(C3=C(OC)C=CC=C3OCCCN)=C2)N=C1
Synonyms :
Ly2606368; ACR 368
MDL No. :MFCD25977016
InChI Key :DOTGPNHGTYJDEP-UHFFFAOYSA-N
Pubchem ID :46700756

Safety of Prexasertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Prexasertib (LY2606368) is distinguished as a highly selective and ATP-competitive second-generation inhibitor of checkpoint kinase 1 (CHK1), possessing a Ki value of 0.9 nM and an IC50 of less than 1 nM. Its ability to inhibit CHK1 with such potency underlines its mechanism of action, which involves causing double-stranded DNA breaks and replication catastrophe, leading to apoptosis. Beyond CHK1, Prexasertib exhibits inhibition against CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM), demonstrating its broad spectrum of action against other kinases involved in cell cycle regulation and tumor growth[1].[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
CRC-SCs (colorectal cancer stem cells) 10 nM, 50 nM, 100 nM 1 hour, 4 hours, 9 hours, 24 hours Assess the impact of LY2606368 on ATM phosphorylation via RPPA analysis, showing LY2606368 induces ATM phosphorylation in sensitive CRC-SCs. PMC5890648
SCLC cell lines 300 nM 120 hours Evaluate the antiproliferative effect of LY2606368 on SCLC cell lines, with IC50 <100 nmol/L in half of the human SCLC cell lines PMC5563854
H460 50 nM 19 days Screen for sgRNAs that increase or decrease cell killing by the CHK1 inhibitor prexasertib PMC7761918
A549 100 nM 19 days Screen for sgRNAs that increase or decrease cell killing by the CHK1 inhibitor prexasertib PMC7761918
OVCAR8 1-40 nM 24 h Increased PARylation was observed even after 24 h exposure at low concentrations PMC11166985
Rh41 (alveolar RMS) 1 μM 24 hours Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. PMC6445779
RD (embryonal RMS) 1 μM 24 hours Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. PMC6445779
SJCRH30 (alveolar rhabdomyosarcoma) 1 μM 24 hours Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. PMC6445779
MG-63 (osteosarcoma) 1 μM 24 hours Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. PMC6445779
A673 (Ewing’s sarcoma) 1 μM 24 hours Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. PMC6445779
H69, H446, and RPP/mTmG cells 1 μM 24 hours Evaluated prexasertib-induced cytogenetic stress. Treatment led to a significant increase in MN frequency (p<0.001). PMC6563834
ML-1 10 nM 24 hours Induced apoptosis, including DNA fragmentation, phosphatidylserine exposure, and cleavage of caspase substrates PMC8137540
THP.1 10 nM 24 hours Induced apoptosis, including DNA fragmentation, phosphatidylserine exposure, and cleavage of caspase substrates PMC8137540
U937 10 nM 24 hours Induced apoptosis, including DNA fragmentation, phosphatidylserine exposure, and cleavage of caspase substrates PMC8137540
SKN 100 nM 24 hours To evaluate the effect of Prexasertib on the cell cycle, results showed that 100 nmol/L Prexasertib significantly reduced the number of G1 phase cells and increased the number of S and G2–M phase cells. PMC9365385
SK-LMS-1 100 nM 24 hours To evaluate the effect of Prexasertib on the cell cycle, results showed that 100 nmol/L Prexasertib significantly reduced the number of G1 phase cells and increased the number of S and G2–M phase cells. PMC9365385
SK-UT-1 10 nM 24 hours To evaluate the effect of Prexasertib on the cell cycle, results showed that 10 nmol/L Prexasertib was sufficient to induce cell-cycle arrest. PMC9365385
NCI-H460 50-100 nM 24 hours To evaluate the effect of CHK1 inhibition on replication stress markers PMC7970065
A549 50-100 nM 24 hours To evaluate the effect of CHK1 inhibition on replication stress markers PMC7970065
Huh-7 cells 5 nM 24 hours To investigate the effect of Prexasertib on apoptosis in Huh-7 cells, results showed that Prexasertib inhibited CHK1 protein levels and promoted cleaved PARP expression, indicating induction of apoptosis. PMC8257880
Hepa1-6 cells 1 µM 24 hours To investigate the effect of Prexasertib on apoptosis in Hepa1-6 cells, results showed that Prexasertib inhibited CHK1 protein levels and promoted cleaved PARP expression, indicating induction of apoptosis. PMC8257880
SKOV3 1 µM 30 min to 8 h Prexasertib treatment caused increased PARylation of proteins, indicating PARP1/2 activation PMC11166985
OVCAR8 1 µM 30 min to 8 h Prexasertib treatment caused increased PARylation of proteins, indicating PARP1/2 activation PMC11166985
TOV112D 1–10 nM 3–6 days To evaluate the cytotoxicity of Prexasertib in ovarian cancer cell lines, results showed that most cell lines were sensitive to Prexasertib with IC50 values of 1–10 nM. PMC6801076
ES2 1–10 nM 3–6 days To evaluate the cytotoxicity of Prexasertib in ovarian cancer cell lines, results showed that most cell lines were sensitive to Prexasertib with IC50 values of 1–10 nM. PMC6801076
UWB1.289 1–10 nM 3–6 days To evaluate the cytotoxicity of Prexasertib in ovarian cancer cell lines, results showed that most cell lines were sensitive to Prexasertib with IC50 values of 1–10 nM. PMC6801076
OVCAR3 1–10 nM 3–6 days To evaluate the cytotoxicity of Prexasertib in ovarian cancer cell lines, results showed that most cell lines were sensitive to Prexasertib with IC50 values of 1–10 nM. PMC6801076
Retinal ganglion cells (RGCs) 10 μM 4 days Prexasertib significantly improved RGC survival and promoted neurite outgrowth. PMC9473583
Adult rat dorsal root ganglion neurons (DRGN) 10 μM 4 days Prexasertib significantly improved DRGN survival (from 40% to 90%) and promoted neurite outgrowth (neurite length increased from 180 μm to 520 μm). PMC9473583
CCRF-CEM SLFN11-del and parental cells 1 μM 4 hours CHK1i treatment for 4 hours induced SLFN11 binding to chromatin and increased the chromatin binding of CDC45 in both parental and SLNF11-del cells PMC5802881
OVCAR8R 3 µM 48 hours Determine the IC50 of Prexasertib on resistant OVCAR8R cells PMC7426265
OVCAR5R 3 µM 48 hours Determine the IC50 of Prexasertib on resistant OVCAR5R cells PMC7426265
OVCAR8 5.4 nM 48 hours Determine the IC50 of Prexasertib on OVCAR8 cells PMC7426265
OVCAR5 7.5 nM 48 hours Determine the IC50 of Prexasertib on OVCAR5 cells PMC7426265
CCRF-CEM cells 100 nM 6 hours To investigate the effect of SLFN11 on chromatin accessibility and IEG transcriptional activation under replication stress. Results showed that SLFN11 enhanced chromatin accessibility and selectively activated IEG transcription. PMC7240837
A673 1 nM 6 hours To evaluate the effect of Prexasertib on CHK1 protein levels and protein synthesis. Results showed that Prexasertib reduced CHK1 protein levels and inhibited protein synthesis. PMC6279492
TC71 1 nM 6 hours To evaluate the effect of Prexasertib on CHK1 protein levels and protein synthesis. Results showed that Prexasertib reduced CHK1 protein levels and inhibited protein synthesis. PMC6279492
EW8 1 nM 6 hours To evaluate the effect of Prexasertib on CHK1 protein levels and protein synthesis. Results showed that Prexasertib reduced CHK1 protein levels and inhibited protein synthesis. PMC6279492
Murine SCLC cell lines (RPP/mTmG) 300nM 72 hours Analyzed cell surface PD-L1 expression by flow cytometry. Prexasertib treatment significantly increased cell surface PD-L1 levels. PMC6563834
Human SCLC cell lines 300nM 72 hours Analyzed PD-L1 protein expression by RPPA, immunoblot, and flow cytometry. DDR targeting significantly increased the total level of PD-L1 protein in all cell lines tested with the greatest PD-L1 fold change (up to 5 fold) with prexasertib. PMC6563834
H82 30 nM 72 hours To evaluate the cytotoxic effects of Prexasertib in combination with cisplatin on SCLC cell lines, results showed that Prexasertib significantly enhanced cisplatin cytotoxicity. PMC6534433
GLC4 30 nM 72 hours To evaluate the cytotoxic effects of Prexasertib in combination with cisplatin on SCLC cell lines, results showed that Prexasertib significantly enhanced cisplatin cytotoxicity. PMC6534433
D425 15 nM 72 hours Evaluate the synergistic effect of Prexasertib with DNA-damaging chemotherapies, results showed Prexasertib significantly enhanced the cytotoxicity of chemotherapies PMC8994821
D283 12 nM 72 hours Evaluate the synergistic effect of Prexasertib with DNA-damaging chemotherapies, results showed Prexasertib significantly enhanced the cytotoxicity of chemotherapies PMC8994821
NSCLC cell lines >0.8 μM Evaluate the antiproliferative effect of LY2606368 on NSCLC cell lines, which were resistant to LY2606368 PMC5563854
OSKG 6.5 nM Prexasertib alone resulted in strongly reduced clonogenic survival, with IC50 of 6.5 nM and IC100 of 20 nM. PMC7384073
OSRH-2011/5 2 nM Prexasertib alone resulted in strongly reduced clonogenic survival, with IC50 of 2 nM and IC100 of 7 nM. PMC7384073
SAOS-2 3 nM Prexasertib alone resulted in strongly reduced clonogenic survival, with IC50 of 3 nM and IC100 of 10 nM. PMC7384073
KHOS-240S 1.7 nM Prexasertib alone resulted in strongly reduced clonogenic survival, with IC50 of 1.7 nM and IC100 of 7 nM. PMC7384073

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CB-17 SCID beige mice Cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models Subcutaneous injection 10 mg/kg Twice daily for 3 days followed by 4 days rest for 3-4 weeks Evaluate the anti-tumor effects of Prexasertib as a monotherapy or in combination with chemotherapy in multiple preclinical models of pediatric cancer. Results showed Prexasertib exhibited significant anti-tumor activity, including complete and partial regressions. PMC6445779
Mice Immunocompetent SCLC model (RPP/mTmG flank tumors) Subcutaneous injection 10 mg/kg 2 days per week, twice daily, for 3 weeks Evaluated the anti-tumor effect of prexasertib in combination with anti-PD-L1 antibody. Remarkable tumor regression was observed in the combination treated group within 1 week, with complete response in 6/10 mice. PMC6563834
NSGS mice SF3B1/RUNX1-mutant MDS patient iPSC-derived HSPCs Subcutaneous injection 10 mg/kg Twice daily for 3 consecutive days followed by 4 days of rest, repeated for 3 weeks Prexasertib selectively eradicated SF3B1-mutant HSPCs, significantly reducing the proportion of engrafted SF3B1-mutant cells PMC11369594
C57BL/6 mice Subcutaneous Hepa1-6 xenograft model Subcutaneous injection 10 mg/kg Twice daily for 2 days followed by 5 days rest, repeated weekly for 3 weeks To investigate the anti-tumor effects of Prexasertib on Hepa1-6 subcutaneous xenografts, results showed that Prexasertib inhibited tumor growth, increased tumor cell apoptosis, and promoted NK cell infiltration. PMC8257880
NCr mice Ewing sarcoma xenograft model Subcutaneous injection 10 mg/kg Twice daily for 3 days, repeated after an 11-day interval To evaluate the effect of Prexasertib alone or in combination with gemcitabine on tumor growth and mouse survival. Results showed that Prexasertib alone caused tumor regression, and the combination with gemcitabine significantly prolonged mouse survival. PMC6279492
Nude mice AML xenograft model Subcutaneous injection 10 mg/kg or 15 mg/kg Every 12 hours on days 1–3, 8–10, 15–17 and 22–24 Evaluated the antileukemic effects of Prexasertib in vivo, showing dose-dependent inhibition of xenograft growth and enhanced host survival PMC8137540
Nude mice SCLC syngeneic model Subcutaneous injection 10 mg/kg, twice daily 3 days per week for 3 weeks Evaluate the antitumor effect of LY2606368 monotherapy in SCLC models, with 6 mice showing complete response and 3 mice showing >75% tumor reduction PMC5563854
Rats T8 dorsal column (DC) crush injury model Intrathecal injection 2 μg Once weekly for 6 weeks Prexasertib significantly suppressed Chk2 phosphorylation, promoted axon regeneration/sprouting, and restored sensory and locomotor function after spinal cord injury. PMC9473583
Mice D425 MB orthotopic xenografts Intravenous injection 20 mg/kg Once weekly for 6 weeks Evaluate the anti-tumor effect of Prexasertib combined with cyclophosphamide, results showed the combination therapy significantly extended the survival of mice PMC8994821
BALB/C nude mice SK-UT-1 tumor model Intraperitoneal injection 3 mg/kg Prexasertib + 3 mg/kg Cisplatin Twice a week for four weeks To evaluate the antitumor effect of Prexasertib in combination with cisplatin, results showed that the combination therapy significantly inhibited tumor proliferation and prolonged the time to tumor progression. PMC9365385
Nude mice SCLC xenograft model Subcutaneous injection 5 mg/kg Twice daily for 3 days followed by 4 days of rest for a total of 3 cycles To evaluate the antitumor activity of Prexasertib alone or in combination with cisplatin in SCLC xenograft models, results showed that Prexasertib significantly enhanced cisplatin antitumor activity and overcame cisplatin resistance. PMC6534433
Immunocompromised mice CRC-SCs xenograft model Subcutaneous injection 5 mg/kg or 10 mg/kg Three cycles of three consecutive days, twice daily, followed by 4 days of rest Evaluate the inhibitory effect of LY2606368 on the growth of CRC-SCs xenografts, showing LY2606368 significantly inhibits tumor growth in sensitive CRC-SCs. PMC5890648
NSG mice HGSOC PDX models Subcutaneous injection 8 mg/kg Twice daily for 3 days, followed by four days of rest and repeated for two additional cycles To evaluate the anti-tumor activity of Prexasertib in HGSOC PDX models, results showed that Prexasertib monotherapy demonstrated significant anti-tumor activity across all models. PMC6801076

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02735980 Small Cell Lung Cancer PHASE2 COMPLETED 2019-02-12 Highlands Oncology Group, Faye... More >>tteville, Arkansas, 72703, United States|Yale University School of Medicine, New Haven, Connecticut, 06520, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Florida Cancer Specialists, Fort Myers, Florida, 33908, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, 33705, United States|Massachusetts General Hospital, Danvers, Massachusetts, 01923, United States|Washington University Medical Center, Saint Louis, Missouri, 63110, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756-0001, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, 37404, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, 37203, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232-6307, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Besancon Cedex, 25030, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, 59037, France|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Montpellier, 34070, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vantoux, 57070, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halle, 06120, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, 11527, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heraklion, 71110, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, 26504, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Seoul, 06351, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, 120-792, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, 1066 CX, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, 4818 CK, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zwolle, 8025 AB, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, 08035, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, 28034, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zaragoza, 50009, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antalya, 07059, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edirne, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, 34098, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, 35100, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, 38039, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dnipropetrovsk, 49102, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kharkiv, 61070, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sumy, 40005, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Headington, OX3 7LJ, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leicester, LE1 5WN, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, S10 2SJ, United Kingdom Less <<
NCT01115790 Advanced Cancer|Squamous Cell ... More >>Carcinoma|Carcinoma, Squamous Cell of Head and Neck|Lung Squamous Cell Carcinoma Stage IV|Anal Squamous Cell Carcinoma|Carcinoma, Non-Small-Cell Lung Less << PHASE1 COMPLETED 2025-01-16 Florida Cancer Specialists, Sa... More >>rasota, Florida, 34232, United States|Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, 37203, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT02514603 Neoplasm PHASE1 COMPLETED 2017-04-10 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, 277 8577, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, 104-0045, Japan Less <<
NCT03414047 Ovarian Cancer PHASE2 COMPLETED 2020-10-03 Arizona Oncology Associates, P... More >>.C., Tucson, Arizona, 85711, United States|Kaiser Permanente Medical Center, Vallejo, California, 94589, United States|University of Southern Florida School of Medicine, Gainesville, Florida, 32610-0296, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Research Medical Center, Kansas City, Missouri, 63142, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756-0001, United States|Cancer Care Associates, Tulsa, Oklahoma, 74146, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Sioux Valley Clinic, Sioux Falls, South Dakota, 57104, United States|University of Tennessee Medical Center, Knoxville, Tennessee, 37920, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, 37203, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Prince of Wales Hospital, Randwick, New South Wales, 2031, Australia|Westmead Hospital, Wentworthville, New South Wales, 2145, Australia|Royal Brisbane and Womens Hospital, Herston, Queensland, 4029, Australia|Mater Adult Hospital Brisbane, South Brisbane, Queensland, 4101, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Burnside War Memorial Hospital, Toorak Gardens, South Australia, 5065, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Institut Jules Bordet, Brussel, 1000, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, 3000, Belgium|GZA St Augustinus, Wilrijk, 2610, Belgium|Rambam Medical Center, Haifa, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Sheba Medical Center, Ramat Gan, 5265601, Israel|Policlinico Univ. Agostino Gemelli, Roma, Lazio, 00168, Italy|Istituto Europeo di Oncologia, Milano, Milan, 20141, Italy|Istituto Tumori Fondazione G. Pascale IRCCS, Napoli, Naples, 80131, Italy|Samsung Medical Center, Seoul, Korea, 06351, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 120-792, Korea, Republic of|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Reina Sofia, Cordoba, 14004, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|University College Hospital - London, London, Greater London, NW1 2BU, United Kingdom|Christie NHS Foundation Trust, Manchester, Greater Manchester, M20 4BX, United Kingdom|Mount Vernon Hospital, Northwood, Middlesex, HA6 2RN, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, GU2 7XX, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, United Kingdom|Northampton General Hospital, Northampton, NN1 5BD, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.74mL

0.55mL

0.27mL

13.68mL

2.74mL

1.37mL

27.37mL

5.47mL

2.74mL

References

 

Historical Records

Categories